A Dark Vector Cognition product

Waters 10-Q 2026-10-03

WAT · CIK 1000697 · Form 10-Q · Period ended October 3, 2026 · Filed November 10, 2026

Revenue rose 121% to $1.77 billion. Operating margin was 7.2%, against 24.0% a year earlier. Net income was $81.0 million.

8 sections, 212K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Oct 3, 2026Quarter ended Sep 27, 2025Change
Revenue$1.77B$800M+121%
Operating income$128M$192M-33.3%
Net income$81.0M$149M-45.6%
Diluted EPS$0.82$2.50-67.2%
Cash and equivalents$593Mn/an/a
Operating margin*7.2%24.0%-16.8 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 109 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 3, 2026

or

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___.

Commission File Number:

001-14010

Waters Corporation

(Exact name of registrant as specified in its charter)

Delaware13-3668640
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

34 Maple Street

Milford,

Massachusetts

01757

(Address, including zip code, of principal executive offices)

(

478-2000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareWATNew York Stock Exchange, Inc.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in

Rule 12b-2

of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in

Rule 12b-2

of the Act). Yes ☐ No ☒

Indicate the number of shares outstanding of the registrant’s common stock as of November 6, 2026: 98,285,634

WATERS CORPORATION AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

INDEX

Page
PART IFINANCIAL INFORMATION
Item 1.Financial Statements1
Consolidated Balance Sheets (unaudited) as of October 3, 2026 and December 31, 20251
Consolidated Statements of Operations (unaudited) for the three months ended October 3, 2026 and September 27, 20252
Consolidated Statements of Operations (unaudited) for the nine months ended October 3, 2026 and September 27, 20253
Consolidated Statements of Comprehensive (Loss) Income (unaudited) for the three and nine months ended October 3, 2026 and September 27, 20254
Consolidated Statements of Cash Flows (unaudited) for the nine months ended October 3, 2026 and September 27, 20255
Consolidated Statements of Stockholders’ Equity (unaudited) for the three months ended October 3, 2026 and September 27, 20256
Consolidated Statements of Stockholders’ Equity (unaudited) for the nine months ended October 3, 2026 and September 27, 20257
Condensed Notes to Consolidated Financial Statements (unaudited)8
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations40
Item 3.Quantitative and Qualitative Disclosures About Market Risk54
Item 4.Controls and Procedures54
PART IIOTHER INFORMATION
Item 1.Legal Proceedings55
Item 1A.Risk Factors55
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds55
Item 5.Other Information56
Item 6.Exhibits57
Signature58

Item 1. Financial Statements

WATERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(unaudited)

October 3, 2026December 31, 2025
ASSETS(In millions, except share data in thousands)
Current assets:
Cash and cash equivalents$593$588
Accounts receivable, net1,464829
Inventories1,324572
Other current assets744159
Total current assets4,1252,148
Property, plant and equipment, net1,458642
Intangible assets, net8,294558
Goodwill9,3691,340
Operating lease assets36381
Other assets506308
Total assets$24,115$5,077
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable$650$460
Accounts payable377104
Accrued employee compensation224100
Deferred revenue and customer advances463267
Current operating lease liabilities5231
Accrued income taxes2536
Accrued warranty2212
Other current liabilities367230
Total current liabilities2,1801,239
Long-term liabilities:
Long-term debt4,483947
Long-term deferred tax liabilities1,60237
Long-term operating lease liabilities31453
Long-term portion of retirement benefits8344
Long-term income tax liabilities2234
Other long-term liabilities140161
Total long-term liabilities6,6441,276
Total liabilities8,8242,515
Commitments and contingencies (Notes 6, 7 and 10)
Stockholders’ equity:
Preferred stock, par value $0.01 per share, 5,000 shares authorized, none issued at October 3, 2026 and December 31, 2025——
Common stock, par value $0.01 per share, 400,000 shares authorized, 201,932 and 163,162 shares issued, 98,272 and 59,549 shares outstanding at October 3, 2026 and December 31, 2025, respectively22
Additional paid-in capital15,3442,416
Retained earnings10,30410,431
Treasury stock, at cost, 103,660 and 103,613 shares at October 3, 2026 and December 31, 2025, respectively(10,177)(10,162)
Accumulated other comprehensive loss(182)(125)
Total stockholders’ equity15,2912,562
Total liabilities and stockholders’ equity$24,115$5,077

The accompanying notes are an integral part of the interim consolidated financial statements.

WATERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended
October 3, 2026September 27, 2025
(In millions, except per share data)
Revenues:
Product revenue$1,334$500
Service revenue433300
Total net revenues1,767800
Costs and operating expenses:
Cost of product revenue670211
Cost of service revenue209117
Selling and administrative expenses398214
Research and development expenses10654
Purchased intangibles amortization24412
Restructuring charges12—
Total costs and operating expenses1,639608
Operating income128192
Interest expense(59)(27)
Interest income65
Income before income taxes74170
Benefit (provision) for income taxes7(21)
Net income$81$149
Net income per basic common share$0.83$2.50
Weighted-average number of basic common shares9860
Net income per diluted common share$0.82$2.50
Weighted-average number of diluted common shares and equivalents9960

The accompanying notes are an integral part of the interim consolidated financial statements.

WATERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Nine Months Ended
October 3, 2026September 27, 2025
(In millions, except share data)
Revenues:
Product revenue$3,473$1,374
Service revenue1,205859
Total revenues4,6782,233
Costs and operating expenses:
Cost of product revenue1,893580
Cost of service revenue577346
Selling and administrative expenses1,187586
Research and development expenses324149
Purchased intangibles amortization64036
Restructuring charges644
Total costs and operating expenses4,6841,701
Operating (loss) income(6)532
Other income, net11
Interest expense(167)(55)
Interest income1713
(Loss) income before income taxes(155)491
Benefit (provision) for income taxes28(73)
Net (loss) income$(127)$417
Net (loss) income per basic common share$(1.37)$7.02
Weighted-average number of basic common shares9359
Net (loss) income per diluted common share$(1.37)$7.00
Weighted-average number of diluted common shares and equivalents9360

The accompanying notes are an integral part of the interim consolidated financial statements.

WATERS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(unaudited)

Three Months EndedNine Months Ended
October 3, 2026September 27, 2025October 3,

Showing the first 8K of 135K characters. Open the full section

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Business Overview

The Company has four operating segments: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences. Analytical Sciences products and services primarily consist of high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLC” and, together with HPLC, referred to as “LC”), mass spectrometry (“MS”), light scattering and field-flow fractionation instruments (Wyatt), and precision chemistry consumable products and related services. Materials Sciences products and services primarily consist of thermal analysis, rheometry and calorimetry instrument systems and service revenue. Biosciences products and services primarily consist of instruments, software and informatics, reagents, and single cell multiomics solutions, supporting the advanced analysis of cell populations for use in fields such as immunology, oncology, and infectious disease research. Advanced Diagnostics products and services primarily consist of a broad range of diagnostic instrumentation, assays, consumables, automation, and informatics that support the detection, identification and drug susceptibility testing of infectious disease organisms.

The Company’s products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic and government customers. These customers use the Company’s products to detect, identify, monitor and measure the chemical, physical and biological composition of materials and to predict the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals and viscous liquids in various industrial, consumer goods and healthcare products.

Acquisition of BD Biosciences and Diagnostic Solutions Businesses

On February 9, 2026 (the “Closing Date”), the Company completed the acquisition (the “BDS Business Acquisition”) of the Biosciences and Diagnostic Solutions business (the “BDS Business”) of Becton, Dickinson and Company (“BD”). The transaction was structured as a Reverse Morris Trust transaction, where the BDS Business was spun off to BD shareholders and simultaneously merged with a wholly-owned subsidiary of the Company. The 2026 financial results of the BDS Business from the Closing Date are included in the Company’s 2026 consolidated financial results presented herein.

Tariffs

The Company sells and services its customers in over 35 countries outside of the U.S. and we have major manufacturing operations in the U.S., Ireland, U.K., Switzerland, Puerto Rico and in Singapore where we utilize subcontractors with worldwide capabilities.

In 2025, the U.S. government issued varying levels of tariffs on all imported goods into the U.S., including a baseline 10% tariff, subject to certain exceptions, which have also prompted retaliatory tariffs by a number of countries, including tariffs and export restrictions on certain manufacturing components imposed by China and tariffs pursuant to trade agreements the U.S. has entered into with certain countries. In addition, a number of new tariffs have been threatened, and the U.S. and other countries continue to negotiate trade arrangements and tariff levels. On February 20, 2026, the U.S. Supreme Court rendered a decision invalidating tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”). On March 4, 2026, the U.S. Court of International Trade ordered the U.S. Customs and Border Protection (“CBP”) to process refunds of the IEEPA tariffs, and the CBP has begun accepting and processing applications for refunds on certain IEEPA tariffs. This decision introduces uncertainty regarding potential refund processes and future trade policy actions and could affect the Company’s cost structure and supply chain planning. As a result of this ruling, the Company may be eligible for a refund of tariffs previously paid on imported goods. As the recoverability and timing of any such refund remains uncertain, the Company has not recognized any material amounts as of October 3, 2026. In response to the U.S. Supreme Court ruling mentioned above, the U.S. government implemented new tariffs under alternative statutory authority. The Company continues to monitor developments around the Supreme Court’s decision and evaluate its potential impact on the Company’s future financial results and business.

These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company’s consolidated statement of operations and statement of cash flows. In response to currently applicable and potential future tariffs, the Company is continuing to evaluate and implement a series of actions and policies that are intended to offset a portion of the impact of the tariffs on the Company’s financial position and results of operations. While the Company believes that these actions and policies will mitigate a substantial portion of the impact of the tariffs, the Company cannot provide any assurances that the tariffs or any resulting impediments to trade will not have a material effect on the Company’s consolidated statement of operations and statement of cash flows.

In addition to changes in trade policy, the U.S. administration has implemented a number of other regulatory, policy and personnel changes, including the elimination, downsizing and reduced funding of certain government agencies and programs and the cancellation or delay of government contracts and research grants. In addition, the administration has changed the composition of and guidance from advisory panels on healthcare practices.

Financial Overview

The Company’s operating results are as follows for the three and nine months ended October 3, 2026 and September 27, 2025 (dollars in millions, except per share data):

Three Months EndedNine Months Ended
October 3, 2026September 27, 2025% changeOctober 3, 2026September 27, 2025% change
Revenues:
Product revenue$1,334$500167%$3,473$1,374153%
Service revenue43330044%1,20585940%
Total net revenues1,767800121%4,6782,233110%
Costs and operating expenses:
Cost of revenue879328168%2,470926167%
Selling and administrative expenses39821486%1,187586103%
Research and development expenses1065496%324149117%
Purchased intangibles amortization24412****64036****
Restructuring charges12—****644****
Operating income (loss)128192(33%)(6)532(101%)
Operating income (loss) as a % of revenue7.2%24.0%(0.1%)23.8%
Other income, net—

Showing the first 8K of 61K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk

The Company is also exposed to the risk of exchange rate fluctuations. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. As of October 3, 2026 and December 31, 2025, $557 million out of $593 million and $372 million out of $588 million, respectively, of the Company’s total cash and cash equivalents were held by foreign subsidiaries. In addition, $380 million out of $593 million and $306 million out of $588 million of cash and cash equivalents were held in currencies other than the U.S. dollar at October 3, 2026 and December 31, 2025, respectively. As of October 3, 2026, the Company had no holdings in auction rate securities or commercial paper issued by structured investment vehicles.

Assuming a hypothetical adverse change of 10% in

year-end

exchange rates (a strengthening of the U.S. dollar), the fair market value of the Company’s cash and cash equivalents held in currencies other than the U.S. dollar as of October 3, 2026 would decrease by approximately $38 million, of which the majority would be recorded to foreign currency translation in other comprehensive income within stockholders’ equity.

Assuming a hypothetical adverse change of 10% in

year-end

exchange rates (a strengthening of the U.S. dollar), the fair market value of the foreign currency exchange contracts outstanding as of October 3, 2026 would not have a material effect on pre-tax earnings. Assuming a hypothetical adverse change of 10% in

year-end

exchange rates (a strengthening of the U.S. dollar), the fair market value of the interest rate cross-currency swap agreements outstanding as of October 3, 2026 would increase by approximately $126 million and would be recorded to foreign currency translation in other comprehensive income within stockholders’ equity. The related impact on interest income would not have a material effect on

pre-tax

earnings.

There have been no other material changes in the Company’s market risk during the nine months ended October 3, 2026. For information regarding the Company’s market risk, refer to Item 7A of Part II of the Company’s Annual Report on Form

10-K

for the year ended December 31, 2025, as filed with the SEC on February 23, 2026.

Item 4. Controls and Procedures

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s chief executive officer and chief financial officer (principal executive officer and principal financial officer),

with

the participation of management, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in

Rules 13a-15(e)

and

15d-15(e)

under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form

10-Q.

Based on this evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective as of October 3, 2026 (1) to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control Over Financial Reporting

No change was identified in the Company’s internal control over financial reporting (as defined in

Rules 13a-15(f)

and

15d-15(f)

under the Exchange Act) during the quarter ended October 3, 2026 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II:

Other Information

Item 1: Legal Proceedings

There have been no material changes in the Company’s legal proceedings during the nine months ended October 3, 2026 as described in Item 3 of Part I of the Company’s Annual Report on Form

10-K

for the year ended December 31, 2025, as filed with the SEC on February 23, 2026.

Item 1A. Risk Factors

Risk Factors

Information regarding risk factors of the Company is set forth under the heading “Risk Factors” under Part I, Item 1A in the Company’s Annual Report on Form

10-K

for the year ended December 31, 2025, as filed with the SEC on February 23, 2026. The Company reviewed its risk factors as of October 3, 2026 and determined that there were no material changes from the ones set forth in the Annual Report on Form

10-K.

Note, however, the discussion of certain factors under the subheading “Special Note Regarding Forward-Looking Statements” in Part I, Item 2 of this Quarterly Report on Form

10-Q.

These risks are not the only ones facing the Company. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial may have a material adverse effect on the Company’s business, financial condition and operating results.

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities by the Issuer

In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a

two-year

period. This program replaced the remaining amounts available under the

pre-existing

authorization. In December 2020, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2023. In December 2022, the Company’s Board of Directors amended and extended this repurchase program’s term by one year such that it expired on January 21, 2024 and increased the total authorization level to $4.8 billion, an increase of $750 million. In December 2023, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2025. In December 2024, the Company’s Board of Directors authorized the extension of the existing share repurchase program through January 21, 2028. As of October 3, 2026, the Company had repurchased an aggregate of 15.2 million shares at a cost of $3.8 billion under the January 2019 repurchase program and had a total of $1.0 billion authorized for future repurchases. The size and timing of these purchases, if any, will depend on our stock price and market and business conditions, as well as other factors.

The following table summarizes the Company’s stock repurchase activity for the three months ended October 3, 2026:

PeriodTotal Number of Shares Purchased (in thousands) (1)Average Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced ProgramsMaximum Dollar Value of Shares That May Yet Be Purchased Under the Programs ( in thousands)
July 5, 2026 to August 1, 20261$366.95—$961,207
August 2, 2026 to August 29, 20262$405.37—$961,207
August 30, 2026 to October 3, 2026—$——$961,207
Total3$392.56—$961,207
(1)All shares repurchased as referenced in the table above related to the vesting of restricted stock during the three months ended October 3, 2026.

Item 5. Other Information

Other Information

Insider Trading Arrangements and Related Disclosures

During the nine months ended October 3, 2026, none of our directors or officers (as defined in Rule

16a-1(f)

under the Exchange Act) adopted, modified or terminated a “Rule

10b5-1

trading arrangement” or

“non-Rule

10b5-1

trading arrangement” (as each term is defined in Item 408 of Regulation

S-K).

Item 6. Exhibits

Exhibit NumberDescription of Document
31.1Chief Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Chief Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **
32.2Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. **
101The following materials from Waters Corporation’s Quarterly Report on Form 10-Q for the quarter ended October 3, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets (unaudited), (ii) the Consolidated Statements of Operations (unaudited), (iii) the Consolidated Statements of Comprehensive (Loss) Income (unaudited), (iv) the Consolidated Statements of Cash Flows (unaudited), (v) the Consolidated Statements of Stockholders’ Equity (unaudited) and (vi) Condensed Notes to Consolidated Financial Statements (unaudited).
104Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101).
**This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WATERS CORPORATION
/s/ Amol Chaubal
Amol Chaubal
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
(Principal Accounting Officer)

Date: November 10, 2026